TABLE 1.
Basic characteristics of included studies.
| Author | Year | Sample size | Country | TNM stage | Treatment | Pathological type | Definition of CONUT score and comparison | Endpoint | NOS |
|---|---|---|---|---|---|---|---|---|---|
| Toyokawa [23] | 2016 | 185 | Japan | I-IV | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. ≥ 2 | OS, PFS | 7 |
| Yoshida [24] | 2017 | 373 | Japan | I-IV | Surgery | EC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; NR | OS, CSS | 7 |
| Hirahara [25] | 2018 | 148 | Japan | I-III | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. 2–4 vs. 5–12 | CSS | 7 |
| Xu [26] | 2018 | 510 | China | I-IV | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. ≥ 2 | OS | 6 |
| Hikage [27] | 2019 | 141 | Japan | I-IV | Surgery | EC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–4 vs. 5–12 | OS, PFS | 6 |
| Sakai [28] | 2020 | 105 | Japan | I-IV | Surgery | EC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT <3 vs. ≥ 4 | OS | 6 |
| Suzuki [29] | 2021 | 241 | Japan | I | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. ≥ 2 | OS | 6 |
| Urabe [30] | 2021 | 224 | Japan | NR | Surgery | EC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. 2–4 vs. 5–12 | OS, CSS | 8 |
| Xu [31] | 2021 | 522 | China | I-IV | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. ≥ 2 | OS | 6 |
| Yoon [32] | 2021 | 1265 | Korea | I-IV | Surgery | SCC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–2 vs. ≥ 3 | OS, PFS | 7 |
| Chang [33] | 2022 | 69 | China | Advanced | Non-surgery | EC | Albumin (g/dL): ≥3.50: 0, 3.00–3.49: 2, 2.50–2.99: 4, <2.50: 6; lymphocyte count (/mm3): ≥1,600: 0, 1,200–1,599: 1, 800–1,199: 2, <800: 3; cholesterol (mg/dL): ≥180: 0, 140–179: 1, 100–139: 2, <100: 3; CONUT 0–1 vs. ≥ 2 | OS, PFS | 7 |
NR, not reported; SCC, squamous cell carcinoma; EC, esophageal cancer; CONUT, controlling nutritional status; OS, overall survival; PFS, progression-free survival; CSS, cancer-specific survival; NOS, Newcastle-Ottawa Scale.